Company news

HLS Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

March 29, 2021

HLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial Results

March 18, 2021

HLS Therapeutics Announces that VASCEPA® (Icosapent Ethyl) is Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021

March 17, 2021

HLS Therapeutics to Host Q4 and Fiscal 2020 Financial Results Conference Call

March 4, 2021

HLS Therapeutics to Participate in Upcoming Virtual Non-Deal Roadshow on February 25, 2021

February 23, 2021

HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on February 18, 2021

February 16, 2021

HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®

February 16, 2021

VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events

January 28, 2021

HLS Therapeutics Announces Final Redemption of Preferred Shares

January 4, 2021

HLS Therapeutics Announces Update on Health Canada Filings for MyCare and Trinomia

December 16, 2020

HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl)

December 14, 2020

HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia

November 17, 2020

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting Procedures

November 16, 2020

HLS Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

November 12, 2020

HLS Therapeutics Announces Q3 2020 Financial Results and Normal Course Issuer Bid

November 5, 2020

HLS Therapeutics to Host Q3 2020 Financial Results Conference Call

October 27, 2020

HLS Therapeutics Highlights Latest Icosapent Ethyl Research Presented at the Canadian Cardiovascular Congress

October 22, 2020

HLS Therapeutics Acquires Portfolio of Four Royalty Interests

September 30, 2020

HLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent Litigation

September 3, 2020

VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020

August 31, 2020

HLS Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

August 7, 2020

HLS Therapeutics Announces Q2 2020 Financial Results

August 6, 2020

HLS Therapeutics to Host Q2 2020 Financial Results Conference Call

July 30, 2020

HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price

July 20, 2020

HLS Therapeutics to Present at the Raymond James Human Health Innovation Conference

June 17, 2020

HLS Therapeutics Confirms Annual Shareholders' Meeting

June 10, 2020

HLS Therapeutics to Present at the Jefferies Virtual Healthcare Conference

June 1, 2020

HLS Therapeutics to Become Distributor of the Saladax MyCare(TM) Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents

June 1, 2020

HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19

May 21, 2020

HLS Therapeutics Announces Q1 2020 Financial Results

May 7, 2020

HLS Therapeutics to Host Q1 2020 Financial Results Conference Call

April 30, 2020

HLS Therapeutics Comments on U.S. District Court Decision on Amarin Patents

March 31, 2020

HLS Therapeutics Announces Fourth Quarter and Fiscal 2019 Financial Results

March 19, 2020

HLS Therapeutics to Host Q4 and Fiscal 2019 Financial Results Conference Call

February 27, 2020

HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)

January 28, 2020

HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada

January 23, 2020

HLS Therapeutics Announces 8 Years of Data Protection for Vascepa®

January 6, 2020

HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events

December 31, 2019

HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa

November 15, 2019

HLS Therapeutics Announces Q3 2019 Financial Results

November 7, 2019

HLS Therapeutics to Host Q3 2019 Financial Results Conference Call

October 24, 2019

HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO(TM)

October 17, 2019

HLS Therapeutics Announces Q2 2019 Financial Results

August 8, 2019

HLS Therapeutics to Host Q2 2019 Financial Results Conference Call

July 25, 2019

HLS Therapeutics Announces Closing of $50 Million Bought Deal Offering

June 5, 2019

HLS Therapeutics to Present at Two Upcoming Conferences

May 30, 2019

HLS Therapeutics Announces $43,500,000 Million Bought Deal Offering

May 14, 2019

HLS Therapeutics Announces Q1 2019 Financial Results

May 9, 2019

HLS Therapeutics Files New Drug Submission for Vascepa® in Canada

April 29, 2019

HLS Therapeutics to Host Q1 2019 Financial Results Conference Call

April 25, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.